ProKidney is a clinical-stage biotechnology company developing rilparencel (REACT), an autologous renal cell therapy intended to help preserve kidney function. The product is made from a patient’s own kidney cells and injected back into the kidney cortex. Development focuses on people with advanced chronic kidney disease, particularly when driven by diabetes, as an alternative path to slow decline toward dialysis.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0.2 | — | -16.6 | — |
| Q3 2025 | 0.2 | — | -16.5 | — |
| Q4 2025 | 0.2 | — | -19.2 | — |
| Q1 2026 | 0.2 | — | -20 | — |
| Q2 2026 | 0.1 | -32.1% | -28.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Yuanbao Inc. (YB), SBC Medical Group Holdings Incorporated (SBC), Array Technologies, Inc. (ARRY), Forward Industries, Inc. (FWDI), Kelly Services, Inc. (KELYA), XMax Inc. (XMAX)